PTGX

Protagonist Therapeutics, Inc.

27.66 USD
+0.88 (+3.29%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Protagonist Therapeutics, Inc. stock is up 12.71% since 30 days ago. The next earnings date is Mar 13, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 7 February’s closed higher than January. In the last 6 Unusual Options Trades, there were 5 PUTs, 1 CALL.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
25 Jan 17:08 19 Apr, 2024 25.00 PUT 200 17
25 Jan 20:42 19 Apr, 2024 25.00 PUT 200 17
29 Jan 19:49 19 Jul, 2024 25.00 PUT 100 0
29 Jan 20:11 19 Jul, 2024 25.00 PUT 100 0
01 Feb 16:00 19 Jul, 2024 25.00 PUT 200 200
02 Feb 16:43 16 Feb, 2024 25.00 CALL 116 99

About Protagonist Therapeutics, Inc.

Protagonist Therapeutics, Inc. discovers and develops peptide-based therapeutic drugs. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis. PN-943, an oral, alpha-4-beta-7 integrin-specific antagonist peptide, is in clinical trials.